GB9201179D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9201179D0
GB9201179D0 GB929201179A GB9201179A GB9201179D0 GB 9201179 D0 GB9201179 D0 GB 9201179D0 GB 929201179 A GB929201179 A GB 929201179A GB 9201179 A GB9201179 A GB 9201179A GB 9201179 D0 GB9201179 D0 GB 9201179D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929201179A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB929201179A priority Critical patent/GB9201179D0/en
Publication of GB9201179D0 publication Critical patent/GB9201179D0/en
Application status is Pending legal-status Critical

Links

GB929201179A 1992-01-21 1992-01-21 Chemical compounds Pending GB9201179D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB929201179A GB9201179D0 (en) 1992-01-21 1992-01-21 Chemical compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929201179A GB9201179D0 (en) 1992-01-21 1992-01-21 Chemical compounds
PCT/EP1993/000101 WO1993014084A2 (en) 1992-01-21 1993-01-15 Piperidine derivatives
AU33513/93A AU3351393A (en) 1992-01-21 1993-01-15 Piperidine derivatives
IL10444593A IL104445D0 (en) 1992-01-21 1993-01-20 Piperidine derivatives,their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
GB9201179D0 true GB9201179D0 (en) 1992-03-11

Family

ID=10708912

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929201179A Pending GB9201179D0 (en) 1992-01-21 1992-01-21 Chemical compounds

Country Status (4)

Country Link
AU (1) AU3351393A (en)
GB (1) GB9201179D0 (en)
IL (1) IL104445D0 (en)
WO (1) WO1993014084A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700472B1 (en) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa synergisante combination with an antagonist of NK1 and NK2 receptors.
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Pharmaceutical agents for treatment or prevention of sunburn.
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
FR2719476B1 (en) * 1994-05-05 1997-05-23 Oreal Use of a substance P antagonist in a cosmetic composition and resulting composition.
FR2719474B1 (en) * 1994-05-05 1996-05-31 Oreal Use of a substance P antagonist in a cosmetic composition and resulting composition.
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265B1 (en) * 1994-12-19 1997-02-07
FR2728165B1 (en) 1994-12-19 1997-02-07
EP0737471A3 (en) * 1995-04-10 2000-12-06 L'oreal Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
FR2732598B1 (en) 1995-04-10 1997-05-09 Oreal Using salt of alkaline earth metals for the treatment of pruritus and ocular dysesthesia or palpebral
FR2737408B1 (en) * 1995-07-31 1997-09-05 Oreal Use of a bradykinin antagonist in a cosmetic composition, pharmaceutical or dermatological composition obtained and
FR2738741B1 (en) * 1995-09-19 1997-12-05 Oreal Composition for dyeing keratin fibers, containing a substance P antagonist
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2740341B1 (en) * 1995-10-26 1997-12-19 Oreal Using lanthanide salt, tin, zinc, manganese, yttrium, cobalt, barium, strontium in a composition for skin
FR2740335B1 (en) * 1995-10-26 1997-12-19 Oreal Using lanthanide salt, lithium, tin, zinc, manganese or yttrium as a substance P antagonist
WO1997045119A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
CA2273785A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
JP2000103782A (en) * 1998-07-31 2000-04-11 Kyorin Pharmaceut Co Ltd Cyclic amine derivative and its production
CA2369695A1 (en) 1999-04-09 2000-10-19 Manabu Itoh Agent for treating neuropathic pain
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
PT1246806E (en) 1999-11-03 2008-04-03 Amr Technology Inc Arly- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
RU2301808C2 (en) 2000-07-11 2007-06-27 Эймр Текнолоджи, Инк. 4-phenyl-substituted tetrahydroisoquinolines, pharmaceutical composition and method for treatment based on thereof
RU2388751C2 (en) 2004-07-15 2010-05-10 Амр Текнолоджи, Инк. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof for inhibiting norepinephrine, dopamine and serotonin reuptake
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (en) 2005-07-15 2009-07-29 Amr科技公司;布里斯托尔-迈尔斯斯奎布公司 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (en) 2008-03-03 2010-12-01 타이거 파마테크 Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
MY158796A (en) 2008-07-03 2016-11-15 Neuraxon Inc Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
ES2528404T3 (en) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Crystalline forms of (S) -7 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4 tetrahydroisoquinoline and its uses
ES2446971T3 (en) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahydroisoquinolines substituted aryl, heteroaryl, and heterocycle and use
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] triazolo [1,5, -a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline and use thereof
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762A1 (en) 2012-05-02 2019-03-13 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
KR20150088257A (en) 2012-11-28 2015-07-31 머크 샤프 앤드 돔 코포레이션 Compositions and methods for treating cancer
JP6387013B2 (en) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208417A (en) * 1978-06-29 1980-06-17 Pharmindustrie Indole derivatives and their use as anxiolytics
FI97540C (en) * 1989-11-06 1997-01-10 Sanofi Sa A process for the preparation of useful aromatically substituted piperidine and piperazine derivatives
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (en) * 1991-05-03 1993-09-03 Sanofi Elf Polycyclic amine compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them.

Also Published As

Publication number Publication date
WO1993014084A3 (en) 1993-10-14
AU3351393A (en) 1993-08-03
WO1993014084A2 (en) 1993-07-22
IL104445D0 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
GB9009861D0 (en) Chemical compounds
GB9007236D0 (en) Chemical compounds
GB9112536D0 (en) Chemical compounds
GB9119920D0 (en) Chemical compounds
GB9119932D0 (en) Chemical compounds
GB9111902D0 (en) Chemical compounds
GB9304618D0 (en) Chemical compounds
GB9304920D0 (en) Chemical compounds
GB9304919D0 (en) Chemical compounds
GB9301000D0 (en) Chemical compounds
GB9326699D0 (en) Chemical compounds
GB9315017D0 (en) Chemical compounds
GB9317987D0 (en) Chemical compounds
GB9312853D0 (en) Chemical compounds
GB9111426D0 (en) Chemical compounds
GB9312210D0 (en) Chemical compounds
GB9307043D0 (en) Chemical compounds
GB9300763D0 (en) Chemical compound
GB9100437D0 (en) Chemical compounds
GB9211686D0 (en) Chemical compounds
GB9222253D0 (en) Chemical compounds
GB9226830D0 (en) Chemical compounds
GB9212693D0 (en) Chemical compounds
GB9201179D0 (en) Chemical compounds
GB9305468D0 (en) Chemical compounds